ReviewChemistry & biodiversity2025
Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition.
Review in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the main cause of dementia worldwide. AD is a progressive brain neurodegenerative disease due to genetic and environmental factors that induce a progressive accumulation of intracellular hyperphosphorylated tau protein and extracellular amyloid protein (Aβ). However, anti-AD medications cannot reverse the fundamental AD neuropathology due to amyloid plaques and related oxidative stress and inflammatory reactions. Thus, targeting other pathways might be reasonable in the management of AD. The serotonin (5-HT) neurotransmitter plays a crucial role in preventing neurodegeneration and related oxidative stress and inflammatory reactions. In addition, the serotonergic system is highly dysregulated in many neurodegenerative diseases, including AD. Deregulation of serotonin synthesis and its receptors is involved in the pathogenesis of AD. Therefore, this review aims to discuss how the serotonergic system is affected in AD, and how 5-HT modulators can reverse AD neuropathology and alleviate the associated neuropsychiatric disorders in AD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.